Artificial Intelligence (AI) in Drug Discovery Market – Global Forecast To 2029
The global artificial intelligence (AI) in drug discovery market is projected to reach 6.89 billion by 2029 from 1.86 billion in 2024, at a CAGR of 29.9% from 2024 to 2029.
創薬市場における世界の人工知能 (AI) は、2024 年の 18 億 6000 万から 2029 年までに 68 億 9000 万に達し、2024 年から 2029 年までの CAGR は 29.9% になると予測されています。
List of Companies Profiled in the Report
o NVIDIA Corporation (US)
o Exscientia (UK)
o Google (US)
o BenevolentAI (UK)
o Recursion (US)
o Insilico Medicine (US)
o Schrödinger, Inc. (US)
o Microsoft (US)
o Atomwise Inc. (US)
o Illumina, Inc. (US)
o Numedii, Inc. (US)
o Xtalpi Inc. (US)
o Iktos (France)
o Tempus (US)
o DEEP GENOMICS (Canada)
o Verge Genomics (US)
o BenchSci (Canada)
o Insitro (US)
o Valo Health (US)
o BPGBio, Inc. (US)
o Merck KGaA (Germany)
o IQVIA (US)
o Tencent Holdings Limited (China)
o Predictive Oncology, Inc. (US)
o CytoReason (Israel)
o Owkin, Inc. (US)
o Cloud Pharmaceuticals (US)
o Evaxion Biotech (Denmark)
o Standigm (South Korea)
o BIOAGE (US)
o Envisagenics (US)
o Abcellera (US)
o Centella (India)
The study includes an in-depth competitive analysis of these key players in the artificial intelligence (AI) in drug discovery market, with their company profiles, recent developments, and key market strategies.
The report provides insights on the following pointers:
- Analysis of key drivers (growing cross-industry collaborations and partnerships, growing need to reduce time and cost of drug discovery and development, patent expiry of several drugs, AI application in oncology areas, integration of multi-omics data, initiatives for research on rare diseases and orphan drugs), restraints (shortage of AI workforce and ambiguous regulatory guidelines for medical software, interpretability of AI), opportunities (growing biotechnology industry, increasing focus on emerging markets, focus on developing human-aware AI systems, increasing use of AI in single cell analysis, rapid expansion of biomarker, disease types, and subtypes identification, growing demand for precision and personalized medicine), and challenges (limited availability of data sets, lack of required tools and usability, computational limitations of advanced AI models, challenges regarding the accessibility of high-quality data) influencing the growth of the artificial intelligence (AI) in drug discovery market
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the artificial intelligence (AI) in drug discovery market
- Market Development: Comprehensive information about lucrative markets – the report analyses the artificial intelligence (AI) in drug discovery market across varied regions.
- Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the artificial intelligence (AI) in drug discovery market
- Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players such as NVIDIA Corporation (US), Exscientia (UK), Google (US), BenevolentAI (UK), Recursion (US), Insilico Medicine (US), Schrödinger, Inc. (US), Microsoft (US), Atomwise Inc. (US), Illumina, Inc. (US), Numedii, Inc. (US), Xtalpi Inc. (US), Iktos (France), Valo Health (US), and Merck KGaA (Germany), among others in artificial intelligence (AI) in drug discovery market.